A partial from 10k Filing :
In 2007, we partnered with Genzyme to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In the first quarter of 2008, we were awarded a contract from the United States Department of Defense ("DoD") pursuant to which we, in partnership with Genzyme, are seeking to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Under the terms of the contract, the DoD will provide funding to us, and if we are successful in obtaining FDA approval for acute radiation syndrome, the contract provides for the purchase of up to 20,000 doses of Prochymal, at $10,000 per dose. Under the terms of this contract, we recognized $470,000 in revenue in fiscal 2010, $2.9 million in revenue in fiscal 2009, and $2.5 million in revenue in fiscal 2008.
Filing link
Note: OSIR shares have not moved as of yet on Japanese radiation, shares trading currently at $6.38 and in fact were much higher just a couple of months ago at $8.50 in mid Dec. 2010. So if investors get any hint like this 10K filing from Monday which was made available for our viewing today then it would not be surprising if (OSIR) shares make its way back to $8.50 levels.
10K filing by OSIR shows it can help Japan with Radiation exposure treatment.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.